Alcami Announces CEO Transition

Rhea-AI Summary

Alcami , a leading contract development and manufacturing organization (CDMO), has announced a leadership transition with Chairman of the Board Patrick Walsh stepping in as Interim CEO following Bill Humphries' resignation. Walsh, who previously served as CEO of Alcami on two occasions and has been Chairman for the past four years, will ensure operational continuity and maintain the company's client-focused approach.

During his two-year tenure, Humphries led Alcami through a period of facilities expansion and global supply chain realignment. Walsh currently holds several leadership positions, including Chairman of ANI Pharmaceuticals (NASDAQ: ANIP), Chairman of MedPharm, and Operating Partner at Ampersand Capital Partners.

News Market Reaction – ANIP

-2.02%

1 alert

-2.02% News Effect

On the day this news was published, ANIP declined 2.02%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries 

DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran.

"On behalf of the Board, I'd like to express gratitude to Bill for his leadership over the last two years during a critical time of facilities expansion and a global supply chain realignment. He was a strong advocate for our clients and the organization benefited from his leadership. I am personally grateful for his contributions and wish him all the best in his new opportunity," commented Walsh.

Mr. Walsh served as CEO of Alcami on two previous occasions and has served as Chairman over the last four years. In addition to his duties at Alcami, he currently serves as Chairman of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), Chairman of MedPharm, and is an Operating Partner at Ampersand Capital Partners.

About Alcami
Alcami is a US-based contract development and manufacturing organization (CDMO) headquartered in NC with 45+ years of experience advancing pharmaceuticals and biologics from development to delivery. Alcami provides fully integrated lab services, drug product manufacturing, and cGMP pharma storage and support services including environmental monitoring, calibration, and validation. Alcami's private equity ownership includes GHO Capital, The Vistria Group, and Ampersand Capital Partners. For more information, please visit alcami.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/alcami-announces-ceo-transition-302349441.html

SOURCE Alcami Corporation

FAQ

Who is replacing Bill Humphries as CEO of Alcami in January 2025?

Patrick Walsh, Alcami's Board Chair and former CEO, is replacing Bill Humphries as Interim CEO.

What major initiatives did Bill Humphries oversee during his tenure at Alcami?

During his two-year tenure, Humphries led Alcami through facilities expansion and global supply chain realignment.

What other leadership positions does Patrick Walsh currently hold?

Patrick Walsh serves as Chairman of ANI Pharmaceuticals (NASDAQ: ANIP), Chairman of MedPharm, and Operating Partner at Ampersand Capital Partners.

How many times has Patrick Walsh previously served as Alcami's CEO?

Patrick Walsh has served as CEO of Alcami on two previous occasions.